Robert W. Kerwin
#156,274
Most Influential Person Now
Robert W. Kerwin's AcademicInfluence.com Rankings
Download Badge
Biology
Why Is Robert W. Kerwin Influential?
(Suggest an Edit or Addition)Robert W. Kerwin's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Functional Connectivity and Brain Networks in Schizophrenia (2010) (1204)
- Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. (2001) (738)
- Association between clozapine response and allelic variation in 5-HT2A receptor gene (1995) (332)
- The –1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity (2004) (267)
- Neuronal Nicotinic Receptors in Dementia with Lewy Bodies and Schizophrenia (1999) (257)
- Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response (1998) (254)
- Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem (1990) (247)
- Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET (1995) (245)
- Active monitoring of 12760 clozapine recipients in the UK and Ireland (1999) (235)
- Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. (2006) (227)
- Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. (1995) (217)
- Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine (1998) (216)
- Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia (1992) (204)
- Do antidepressants regulate how cortisol affects the brain? (2004) (200)
- CORONARY ARTERY INFUSION OF NEUROPEPTIDE Y IN PATIENTS WITH ANGINA PECTORIS (1987) (199)
- Association between clozapine response and allelic variation in the 5-HT2C receptor gene (1995) (183)
- Limbic selectivity of clozapine (1997) (173)
- Cortical serotonin 5-HT2A receptor binding and social communication in adults with Asperger's syndrome: an in vivo SPECT study. (2006) (172)
- RNA editing of the 5-HT2C receptor is reduced in schizophrenia (2001) (168)
- The New Atypical Antipsychotics (1994) (154)
- Reduced levels of GABA-benzodiazepine receptor in alcohol dependency in the absence of grey matter atrophy (1998) (150)
- Dopamine D4 receptor subtypes and response to clozapine (1993) (148)
- Decreased hippocampal expression of a glutamate receptor gene in schizophrenia (1991) (146)
- Brain blood flow in anxiety disorders (1997) (135)
- D2 Dopamine Receptor Binding in the Basal Ganglia of Antipsychotic-Free Schizophrenic Patients (1994) (131)
- Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine (1996) (129)
- Schizophrenia: A Neurodevelopmental Perspective (1993) (127)
- Evidence that RNA editing modulates splice site selection in the 5-HT2C receptor gene. (2004) (112)
- Is there cognitive impairment in clinically 'healthy' abstinent alcohol dependence? (2005) (111)
- A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study (2007) (110)
- Regional Cerebral Blood Flow in Obsessive-Compulsive Disordered Patients at Rest (1995) (107)
- Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study (1993) (103)
- Evidence that the N-methyl-D-aspartate subunit 1 receptor gene (GRIN1) confers susceptibility to bipolar disorder (2003) (102)
- Immunoautoradiographic evidence for a loss of α-amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non-N-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia (1997) (102)
- Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. (1997) (102)
- Association analysis of the 5‐HT5A gene in depression, psychosis and antipsychotic response (2000) (95)
- DRD2 Ser311/Cys311 polymorphism in schizophrenia (1994) (95)
- Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia (2003) (91)
- Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia (1996) (89)
- Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study (2000) (86)
- Clinical applications of pharmacogenetics in psychiatry (2002) (81)
- Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography(SPET) study. (2000) (80)
- Cost-effectiveness of clozapine (1997) (77)
- Association analysis of the catechol O-methyltransferase gene and bipolar affective disorder. (1997) (76)
- The Antidepressant Clomipramine Regulates Cortisol Intracellular Concentrations and Glucocorticoid Receptor Expression in Fibroblasts and Rat Primary Neurones (2003) (76)
- Cytochrome P450IID6 genotype does not determine response to clozapine (1995) (75)
- Clomipramine In Vitro Reduces Glucocorticoid Receptor Function in Healthy Subjects but not in Patients with Major Depression (2008) (75)
- Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. (1998) (72)
- A novel prednisolone suppression test for the hypothalamic-pituitary-adrenal axis (2002) (70)
- Elevation of D4 dopamine receptor mRNA in postmortem schizophrenic brain. (1998) (70)
- 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine (1998) (69)
- No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response (2000) (68)
- Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients. (1995) (67)
- Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response (2002) (66)
- 5HT2a receptor T102C polymorphism and schizophrenia (1996) (65)
- The Maudsley 2005-2006 Prescribing Guidelines (2005) (64)
- Role of Chronic Infection and Inflammation in the Gastrointestinal Tract in the Etiology and Pathogenesis of Idiopathic Parkinsonism (2005) (64)
- Lithium and clozapine rechallenge: a retrospective case analysis. (2006) (64)
- Disturbance of Notch-1 and Wnt signalling proteins in neuroglial balloon cells and abnormal large neurons in focal cortical dysplasia in human cortex (1999) (61)
- Association of the dysbindin gene with bipolar affective disorder. (2006) (61)
- Role of Chronic Infection and Inflammation in the Gastrointestinal Tract in the Etiology and Pathogenesis of Idiopathic Parkinsonism (2005) (60)
- Suicide risk and the SSRIs. (2004) (59)
- Increased dendritic MAP2 expression in the hippocampus in schizophrenia (2000) (59)
- Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. (2003) (57)
- An RT-PCR study of 5-HT6 and 5-HT7 receptor mRNAs in the hippocampal formation and prefrontal cortex in schizophrenia (2002) (56)
- Four days of citalopram increase suppression of cortisol secretion by prednisolone in healthy volunteers (2004) (56)
- In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs (1999) (54)
- Alterations in hippocampal non-phosphorylated MAP2 protein expression in schizophrenia (1997) (53)
- 5-HT2A receptor and bipolar affective disorder: association studies in affected patients (1997) (52)
- The serotonin transporter and clozapine response (2000) (52)
- A dopamine D2 receptor gene-related polymorphism is associated with schizophrenia in a Spanish population isolate (2007) (51)
- Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response (2002) (50)
- Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: A 1231-iomazenil SPET study (1998) (50)
- Association between dopamine D3 receptor gene polymorphisms and schizophrenia in an isolate population (2005) (49)
- Role of Pharmacogenomics in Individualising Treatment with SSRIs (2003) (48)
- IQ in childhood psychiatric attendees predicts outcome of later schizophrenia at 21 year follow‐up (2002) (47)
- A developmental perspective on the pathology and neurochemistry of the temporal lobe in schizophrenia (1992) (47)
- Management of clozapine-resistant schizophrenia (2005) (47)
- New Antipsychotics (1996) (46)
- Stargazin involvement with bipolar disorder and response to lithium treatment (2008) (46)
- The Antidepressant Desipramine Requires the ABCB1 (Mdr1)-Type p-Glycoprotein to Upregulate the Glucocorticoid Receptor in Mice (2007) (45)
- Polymorphisms in the genes for mGluR types 7 and 8: association studies with schizophrenia (2001) (44)
- In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole – a 123I IBZM single photon emission tomography (SPET) study (1997) (44)
- Partial agonism and schizophrenia (2005) (43)
- Systematic screening of the 14-3-3 eta (eta) chain gene for polymorphic variants and case-control analysis in schizophrenia. (2000) (42)
- Caudate regional cerebral blood flow in obsessive-compulsive disorder, panic disorder and healthy controls on single photon emission computerised tomography (1997) (41)
- Pharmacogenetic studies of change in cortisol on ecstasy (MDMA) consumption (2012) (39)
- Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation. (1999) (39)
- Systematic screening of the LDL-PLA2 gene for polymorphic variants and case-control analysis in schizophrenia. (1997) (38)
- Decreased expression of AMPA receptor messenger RNA and protein in AIDS: A model for HIV-associated neurotoxicity (1995) (37)
- Regional cerebral blood flow (rCBF) in schizophrenia during verbal memory activation: a 99mTc-HMPAO single photon emission tomography (SPET) study (1994) (37)
- Schizophrenia, psychosis, and the basal ganglia. (1997) (36)
- Identification of novel polymorphisms in the 5' flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance. (2000) (36)
- Pharmacogenetics for the Individualization of Psychiatric Treatment (2001) (36)
- The regional pattern of D4 gene expression in human brain (1997) (36)
- The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients. (2004) (35)
- Pathology, Phenomenology, and the Dopamine Hypothesis of Schizophrenia (1988) (35)
- Clozapine pharmacokinetics and pharmacodynamics studied with CYP1A2-null mice (2000) (35)
- Genetic Predictors of Therapeutic Response to Clozapine (2002) (35)
- Initial evaluation of123I-5-I-R91150, a selective 5-HT2A ligand for single-photon emission tomography, in healthy human subjects (1997) (35)
- No difference in the expression of the D4 gene in post-mortem frontal cortex from controls and schizophrenics (1996) (34)
- Archives of General Psychiatry, June 1991 (1991) (34)
- Serotonergic polymorphisms and psychotic disorders in populations from North Spain (2004) (33)
- An Open Letter to the President (1957) (32)
- Effect of Clozapine on d-Fenfluramine-Evoked Neuroendocrine Responses in Schizophrenia and its Relationship to Clinical Improvement (1995) (31)
- Left Temporal Lobe Damage in Asperger's Syndrome (1990) (31)
- Increased forskolin binding in the left parahippocampal gyrus and CA1 region in post mortem schizophrenic brain determined by quantitative autoradiography (1990) (30)
- A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. (2000) (29)
- Cost-effectiveness of clozapine (1997) (29)
- Glutamate receptors, microtubule associated proteins and developmental anomaly in schizophrenia: an hypothesis (1993) (29)
- Distribution of CCK binding sites in the human hippocampal formation and their alteration in schizophrenia: a post-mortem autoradiographic study (1992) (28)
- Stereotypy, schizophrenia and dopamine D2 receptor binding in the basal ganglia (1994) (28)
- AMPA glutamate receptors and their flip and flop mRIMAs in human hippocampus (1994) (27)
- Polymorphisms in the Promoter Region of the Alpha1A-Adrenoceptor Gene Are Associated with Schizophrenia/Schizoaffective Disorder in a Spanish Isolate Population (2005) (26)
- When Should Clozapine Be Initiated in Schizophrenia? (2007) (25)
- Expression of Oct-6, a POU III domain transcription factor, in schizophrenia. (2002) (25)
- The Maudsley 2003 Prescribing Guidelines (2003) (25)
- Schizophrenic auditory hallucinations are associated with increased regional cerebral blood flow during verbal memory activation in a study using single photon emission computed tomography (1995) (24)
- Is clozapine antisuicidal? (2004) (24)
- From pharmacological profiles to clinical outcomes. (2000) (23)
- Latent inhibition in drug naive schizophrenics (1993) (23)
- Heat Stroke in Schizophrenia During Clozapine Treatment: Rapid Recognition and Management (2004) (23)
- A Risk-Benefit Assessment of Risperidone in Schizophrenia (1995) (23)
- Erratum: Initial evaluation of 123 I-5-I-R91150, a selective 5-HT(2A) ligand for single-photon emission tomography, in healthy human subjects (European Journal of Nuclear Medicine (1997) 24 (119-124)) (1997) (20)
- Applications of pharmacogenetics in psychiatry: personalisation of treatment (2001) (20)
- Initial evaluation of 123I-5-I-R91150, a selective 5-HT2A ligand for single-photon emission tomography, in healthy human subjects. (1997) (19)
- Atypical antipsychotics in the treatment of schizophrenia (2001) (19)
- Pharmacogenomics--can genetics help in the care of psychiatric patients? (2004) (19)
- Dopamine D2 receptor occupancy in vivo and response to the new antipsychotic risperidone (1993) (19)
- Ecstasy (MDMA)-induced hyponatraemia is associated with genetic variants in CYP2D6 and COMT (2012) (18)
- Bipolar 1 disorder is not associated with the RGS4, PRODH, COMT and GRK3 genes. (2006) (18)
- Striatal and extra-striatal D2/D3 dopamine receptor occupancy by quetiapine in vivo (2000) (17)
- The histamine 1 and histamine 2 receptor genes - candidates for schizophrenia and clozapine drug response (2000) (17)
- Reduced glial density and neuronal volume in major depressive disorder and schizophrenia in the anterior cingulate cortex (2000) (16)
- Serotonin: 5-HT2A receptor occupancy in vivo and response to the new antipsychotics olanzapine and sertindole (1997) (16)
- Prescribing in schizophrenia. Evaluating the effect of introducing a new treatment protocol (2000) (16)
- Analysis of structural polymorphisms and C-1018G promoter variant of the 5-HT1A receptor gene as putative risk factors in major depression (2003) (15)
- GABAergic inhibitory mechanisms for repetition-adaptivity in large-scale brain systems (2003) (15)
- Advances in the pharmacogenetic prediction of antipsychotic response. (2003) (15)
- Biological Determinants of Difficult to Treat Patients with Schizophrenia (1996) (14)
- The dopamine D4 receptor in schizophrenia: an update (1996) (14)
- Pharmacological treatment of schizophrenia (2005) (13)
- Genetics of novel therapeutic targets in schizophrenia (1999) (13)
- A comparison of the effects of acute and one year's continuous neuroleptic treatment on the release of [3H]glutamate and [3H]acetylcholine from rat striatal slices (1984) (13)
- Functional neuroimaging and pharmacogenetic studies of clozapine's action at dopamine receptors. (1994) (12)
- Dopamine D4 Receptors (1997) (12)
- Adverse reaction reporting and new antipsychotics (1993) (12)
- Connecting patient needs with treatment management (2009) (12)
- Neurobiology and psychiatry (1991) (12)
- In vivo serotonin 5-HT(2A) receptor occupancy and quetiapine. (2000) (12)
- Traditional receptor theory and its application to neuroreceptor measurements in functional imaging (1995) (11)
- How do the neuropathological changes of schizophrenia relate to pre-existing neurotransmitter and aetiological hypotheses? (1989) (11)
- Rediscovering monoamine oxidase inhibitors. (1989) (11)
- Long-term adaptive changes in striatal dopamine function in response to chronic neuroleptic intake in rats. (1983) (11)
- [Influence of serotonergic transmission on response to olanzapine]. (2002) (10)
- Clozapine in the management of schizophrenia. All schizophrenic patients would benefit. (1993) (10)
- Clozapine: back to the future for schizophrenia research (1995) (10)
- Merck, Sharp & Dohme Prize for Young Psychopharmacologists (1992) (10)
- Expression of alternatively-spliced glutamate receptors in human hippocampus. (1993) (9)
- A polymorphism in the promoter region of the dopamine D2 receptor gene (DRD2) and drug response: Association studies (1998) (9)
- An essay on the use of new antipsychotics (1996) (9)
- Diethylpropion Hydrochloride-Induced Psychosis (1988) (9)
- Pharmacoeconomics in Psychiatry (2002) (8)
- Use of psychotropics in special patient groups (2005) (8)
- Neurotransmitter receptor variants and their influence on antipsychotic treatment (Review)). (2001) (8)
- Schizophrenia and the androgen receptor gene: report of a sibship showing co-segregation with Reifenstein syndrome but no evidence for linkage in 23 multiply affected families. (1995) (8)
- A Perspective on Progress in Pharmacogenomics (2003) (7)
- In vivo imaging of GABAA receptors using sequential whole-volume iodine-123 iomazenil single-photon emission tomography (2005) (7)
- A randomised, controlled trial of new atypical drugs versus clozapine in treatment-resistant schizophrenia [Abstract]. 12th Biennial Winter Workshop on Schizophrenia, Davos, Switzerland. (2004) (7)
- Pharmacogenomics of psychiatric drug treatment. (2003) (7)
- Complications of pregnancy and delivery and psychosis in adult life. (1991) (7)
- Serotonin-6 (5-HT6) receptor variant association study with clozapine and olanzapine response (2001) (6)
- 419. Striatal D2 blockade and depression in schizophrenia—SPET findings (2000) (6)
- First generation versus second generation (non-clozapine) antipsychotic drugs versus clozapine in schizophrenia: The CUtLASS trials [Abstract]. 44th Annual Meeting of American College of Neuropsychology (ACNP), Waikoloa, Hawaii, US. (2005) (6)
- Cost analysis of treating schizophrenia with amisulpride: Naturalistic mirror image study (2005) (6)
- Decreased absolute levels of ascorbic acid and unaltered vasoactive intestinal polypeptide receptor binding in the frontal cortex in acquired immunodeficiency syndrome (1997) (6)
- Genetic strategies for the personalization of antipsychotic treatment (2001) (6)
- D4 polymorphisms in schizophrenic patients treated with clozapine (1995) (6)
- What have we learned about the biology of schizophrenia (1988) (5)
- Expression of the α1A-adrenergic receptor in schizophrenia (2006) (5)
- Receptor pharmacogenetics: relevance to CNS syndromes. (2002) (5)
- P.1.178 Association between the serotonin transporter linked polymorphic region gene (5-HTTLPR) and response to tricyclic antidepressants (TCAs) (2003) (5)
- A controlled, mirror-image study of second-generation antipsychotics in the treatment of schizophrenia (2007) (5)
- Pharmacogenetic and Pharmacogenomic Research in Psychiatry: Current Advances and Clinical Applications (2003) (5)
- Brain blood flow in anxiety disorders: OCD panic and PTSD (1997) (5)
- Treatment challenges in schizophrenia (1999) (5)
- No alterations in the density of parvalbumin or calretinin immunoreactive neurons in the anterior cingulate cortex (BA 24b/c) in schizophrenia or bipolar disorder (2000) (5)
- Developments in the pharmacological treatment of schizophrenia (2002) (5)
- Association between clozapine response and allelic variation in the 5-HT2A and 5-HT2C receptor genes (1996) (4)
- P.1.32 Association between the serotonin transporter linked polymorphic region gene and response to tricyclic antidepressants (2005) (4)
- Association analysis of muscarinic acetylcholine receptor polymorphisms in clozapine treated schizophrenics. (2000) (4)
- Antipsychotic response prediction by genotype. (2000) (4)
- Olanzapine was more effective than lorazepam at 2 hours but not at 24 hours in bipolar mania with acute agitation (2002) (4)
- 2003 PRESCRIBING GUIDELINES (2003) (4)
- Displacement of the selective 5-HT2A ligand 123I-5-I-R91150 by unlabelled ketanserin (2000) (3)
- Non-NMDA glutamate receptor expression in schizophrenia (1996) (3)
- Positive association of CYP2D6 and COMT variants with ecstasy-induced changes in water homeostatic measures (2006) (3)
- A comparative study of quetiapine and risperidone in patients with first-episode psychosis (2005) (3)
- SCHIZOPHRENIA INDUCED BY RESTITUTION OF THYROID FUNCTION IN A PREDISPOSED PATIENT (1989) (3)
- The expression of NMDA receptor subunits in schizophrenic post-mortem human hippocampus (1995) (3)
- Pharmacogenetic and pharmacogenomic research for the prediction of response to antipsychotics in schizophrenia (2003) (3)
- 5th International Congress of Neuroendocrinology (2002) (3)
- Expression of the alpha1A-adrenergic receptor in schizophrenia. (2006) (3)
- Efficacy, discontinuation and side effects of atypical antipsychotics in first-episode psychosis (2004) (3)
- Pharmacogenetic methods in schizophrenia (2001) (3)
- An association study of the CYP1A2 C-164A and T-3591G polymorphisms and response to clozapine (2004) (3)
- Functional increase in striatal dopaminergic activity following continuous long-term treatment with trifluoperazine (1984) (3)
- Discontinued drugs in 2005: schizophrenia drugs (2006) (3)
- Association of a D2 receptor gene polymorphism with schizophrenia and treatment response in the Basque and Spanish populations (2004) (3)
- Pharmacogenetic prediction of olanzapine response (2002) (2)
- Examination of the DRD2 (SER-CYS) variant in schizophrenia (1995) (2)
- Alterations in the cytoplasmic state of neuronal beta and gamma catenin in the hippocampus in schizophrenia (1998) (2)
- DRD2 Ser311/Cys311 polymorphism in schizophrenia. (1994) (2)
- Serotonin-6 (5-HT6) receptor variant (267-C/T) not associated with clozapine response. (2000) (2)
- Modelling the impact of clozapine on suicide Modelling the impact of clozapine on suicide in patients with treatment-resistant in patients with treatment-resistant schizophrenia in the UK schizophrenia in the UK (2003) (2)
- Dopamine receptor genes and schizophrenia: the tail wags the dog? (1994) (2)
- Neurodevelopmental Model of Schizophrenia (1988) (2)
- The National Institute for Clinical Excellence and its relevance to pharmacology. (2004) (2)
- Polymorphisms in the dopamine D2 receptor gene: A study of association with schizophrenia in a spanish population isolate (2005) (2)
- The House of Commons Health Committee: ‘The Influence of the Pharmaceutical Industry’ – too much too late? (2007) (2)
- Investigation of a novel muscarinic 1 receptor polymorphism on receptor expression in schizophrenia (2002) (2)
- 512 Preliminary report: Effecrs of clozapine and typical antipsychotics on striataland limbic dopamine D2/D2-like receptors in vivo by 123I epidepride spet (1997) (2)
- Monoamine Oxidase Inhibitors: 30 Years Of Progress? (1990) (2)
- Neuroleptic sensitivity and enzyme deficiency in two schizophrenic brothers: A case report (1996) (2)
- The spatial pattern of parvalbumin immuno-reactive neurons in the anterior cingulate cortex (BA 24b/c) in schizophrenia and bipolar disorder (2000) (2)
- Neurochemistry of Consciousness. Neurotransmitters in Mind (2003) (2)
- Preventing suicide (2003) (2)
- Pharmacogenetic studies of tricyclic antidepressant response and an association study of a noradrenaline transporter variant in depression (2002) (2)
- Hippocampal synaptophysin gene expression in schizophrenia (1993) (2)
- Decreased dopamine D2 receptor binding potential in the basal ganglia after augmenting clozapine treatment with amisulpride: A 123-I-IBZM SPET-study (2001) (2)
- Individualisation of treatment: Genetic prediction of clozapine response (2000) (2)
- Novel polymorphisms detected in the 5-HT3 receptor gene: Association studies with schizophrenia and clozapine response (1997) (2)
- Gene Expression in Down’s Syndrome, Parkinson’s Disease, and Schizophrenia (1994) (2)
- Equiefficacy of quetiapine versus risperidone in the treatment of depression in patients in their first episode of a schizophreniform psychotic illness: Interim results of an 8 week randomised single blind trial (2005) (2)
- The neurochemical anatomy of the hippocampus in post-mortem schizophrenic brain (1990) (2)
- 142 A linkage disequilibrium study of chromosome 4p16 and schizophrenia (1997) (2)
- Novel histamine H1 gene polymorphism and clozapine-induced weight gain (2000) (2)
- 247 Apolipoprotein E and schizophrenia: Association with clinical response to clozapine (1997) (1)
- Investigation of 5-HT2A differential expression and imprinting in schizophrenia. (2000) (1)
- The role of atypical antipsychotic drugs in schizophrenia (2001) (1)
- Influence of polymorphisms in serotonin receptors on response to atypical antipsychotics. (2000) (1)
- Antipsychotic adverse reactions in schizophrenia: A pharmacogenetic study of weight gain and tardive dyskinesia. (2000) (1)
- 5HT 2a receptor T102C polymorphism and schizophrenia. (1996) (1)
- Pharmacogenetics of Psychotropic Drugs: Clozapine response and genetic variation in neurotransmitter receptor targets (2002) (1)
- Relative quantification analysis of cortical histamine 1 and muscarinic 1 receptor expression in patients with schizophrenia (2001) (1)
- Loss of non nmda receptors in medial temporal lobe—-a robust neurochemical finding: autoradiographical, gene expression and immunocytochemical findings (1995) (1)
- Allelic variations in CYP450 enzymes and olanzapine response (2004) (1)
- MDMA: Stress regulation, cortisol, 5-HTTLPR and COMT polymorphisms (2006) (1)
- 235 Polymorphisms in the 5-HT2A receptor gene and promoter region associated with clozapine response (1997) (1)
- Brain imaging techniques and applications. Edited By N. A. Shaiuf and M. E. Lewis. Ellis Horwood, Chichester. no. of pages: 293. Price: £32.50 (1991) (1)
- The molecular mechanisms by which the proinflammatory cytokine, interleukin-1, influences the glucocorticoid receptor: Relevance for glucocorticoid resistance and major depression (2000) (1)
- The answer lies within selective ligands and pharmacogenomics. (1999) (1)
- Association study of the CYP1A2 C(164)A polymorphism and tardive dyskinesia (TD) (2002) (1)
- The cutlass study: A pragmatic, multicentre trial of the effectiveness and costs of atypical antipsychotic drugs in schizophrenia (2000) (1)
- P.3.c.028 Effectiveness of aripiprazole versus standard of care treatment in patients with schizophrenia: the Schizophrenia Trial of Aripiprazole (STAR) study (2006) (1)
- Homozygosity at the DRD3 does not influence response to clozapine (1995) (1)
- Central D2 dopaminergic receptor status in treatment responsive and treatment resistant schizophrenic patients as measured by 123I-IBZM single photon emission tomography (SPET) (1991) (1)
- The functional G-protein β3 subunit (C825T) polymorphism does not influence the efficacy of olanzapine therapy in Basque or Spanish patients (2003) (1)
- CATIE for clinicians (2006) (1)
- Psychiatric Genetics and Genomics (2002) (1)
- A second novel polymorphism in the promotor region of the N-acetyltransferase gene (AA-NAT) is not associated with schizophrenia or bipolar affective disorder (1998) (1)
- Antidepressants Increase Intracellular Concentration of Cortisol by Modulating a Membrane Steroid Transporter (2002) (1)
- Gender differences in the pattern of reduced levels of the GABA benzodiazepine receptor in alcohol dependency - An L23 I-iomazenil SPECT and MRI study. (1998) (1)
- Raw deal for academics (1992) (1)
- Association study between the serotonin transporter linked polymorphic region (5-HTTLPR) and cortisol response in ecstasy users (2003) (1)
- Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (2001) (1)
- Initial evaluation of123|-5-|-R91150, a selective 5-HT2A ligand for single-photon emission tomography, in healthy human subjects (2006) (1)
- FC4A 12 WEEK RANDOMISED BLINDED TRIAL OF QUETIAPINE VERSUS RISPERIDONE: RELATIVE ANTIPSYCHOTIC EFFICACIES AND SIDE EFFECTS (2006) (1)
- Increased basal ganglia blood flow during memory activation in schizophrenia, relationship with auditory hallucinations (1995) (1)
- 47. D2 dopamine receptor abnormalities in schizoprhenia: a 123I-IBZM SPET study (1993) (1)
- 499 5-HT2A receptor blockade in vivo in schizophrenic patients treated with atypical antipsychotics: Single photon emission tomography (SPET) findings (1997) (1)
- Typical antipsychotics lead to 5-HT2A receptor blockade In vivo in schizophrenic patients: Initial single photon emission tomography (SPET) findings (1998) (1)
- Chromosomal mapping, mutation screening and association analysis of the histamine 3 receptor in clozapine treated people with schizophrenia (2001) (1)
- The D3 receptor and improvement in positive symptoms of schizophrenia (2002) (1)
- Applications of pharmacogenetics in psychiatry (2004) (1)
- CYP2D6 genotype and treatment with tricyclic antidepressants (2002) (0)
- O-10-5 Cerebral blood flow and WCST in OCD (1996) (0)
- Preliminary cost analysis of treating schizophrenia with amisulpride: An ongoing naturalistic mirror image study (2003) (0)
- Dopamine D3 receptor gene polymorphisms influence olanzapine and risperidone response (2004) (0)
- No association between a variable number of tandem repeat (VNTR) in the 3 ' untranslated region of the dopamine transporter gene (DAT1) and bipolar affective disorder (1998) (0)
- Pharmacogenetic prediction of ziprasidone response in schizophrenic patients (2005) (0)
- The role of nerve growth factor in Alzheimer's disease (1990) (0)
- Amisulprideof its Use in the Management of Schizophrenia (2001) (0)
- The neurobiology of psychoses (2000) (0)
- The-1438-A/G serotonin 2A receptor promoter polymorphism affects promoter activity (2003) (0)
- Preliminary cost analysis of amisulpride - A naturalistic mirror image study (2002) (0)
- Pharmacological Treatment of the Newly Diagnosed Patient with Schizophrenia (1997) (0)
- Analysis of the NMDA receptor in schizophrenia (1997) (0)
- ASSOCIATION BETWEEN ALPHA2-RECEPTOR VARIANTS AND MOVEMENT DISORDERS (2008) (0)
- The effect of d-fenfluramine on 123I-5-I-R91150 binding to 5-HT2A receptors in vivo - pilot data (1998) (0)
- Expression of developmentally specific forms of glutamate receptor mRNAs in the hippocampus of schizophrenics (1993) (0)
- Analysis of candidate genes for prospectively assessed response to lithium in a collection of bipolar disorder patients from Sardinia (2006) (0)
- SPET imaging of cortical muscarinic receptors with [(123)I]R,R-I-QNB (2003) (0)
- Effect of long-term estrogen replacement therapy on cortical 5-HT (2A) receptor density (2003) (0)
- S.25.05 Cost-effectiveness of treatments for schizophrenia (1996) (0)
- The development of a semi-quantitative assay for D4 gene expression (1996) (0)
- P.2.117 Development of a genetic test for the prediction of clozapine response (2003) (0)
- Psychiatric Neuroscience Old: Wine in New Bottles (1995) (0)
- Activation by dexamethasone of a new green fluorescent protein-glucocorticoid receptor (GR) chimera in cell lines and rat cortical neurones (2000) (0)
- IN VIVO PHARMACOLOGY OF ANTIPSYCHOTIC DRUGS (1998) (0)
- Genetic predictors of olanzapine response (2001) (0)
- An association study of the 5-HT6 267-C/T polymorphism and antipsychotic response (2001) (0)
- D3 receptor polymorphisms and improvement in positive symptoms in schizophrenia (2002) (0)
- 45. D2 dopamine receptor blockade and response to anti-psychotic treatment: a 123I-IBZM SPET study (1993) (0)
- 81 Lateralised alterations in hippocampal MAP2 in schizophrenia (1997) (0)
- Genetics and the pharmacokinetics and pharmacodynamics of psychiatric drugs (2005) (0)
- Author retraction. (2006) (0)
- The use of olanzapine in a UK NHS trust (2000) (0)
- Progress in pharmacogenetic and pharmacogenomic investigation of antipsychotic response (2004) (0)
- 242 The spatial expression patern of the D4 gene in the human brain (1997) (0)
- An amino acid substitution (Ile109Val) in CYP2D6 (2002) (0)
- 238 Allelic variation of the 5-HT2C receptor in psychosis (1997) (0)
- SPECT, MRI and cognitive studies in alcohol dependence (1998) (0)
- Clinical applications of pharmacogenetics: Pre-treatment prediction of antipsychotic response (2003) (0)
- S.4.02 Dopamine 3 (D3) receptors genetic variants: influence in schizophrenia and antipsychotic response (2004) (0)
- 123I-IBZM SPECT brain imaging in schizophrenia (1995) (0)
- Antidepressants enhance intracellular access of cortisol in primary rat neurones (2002) (0)
- The use of pharmacogenetics for prediction of antipsychotic response (2002) (0)
- ADRA1A promoter polymorphisms associated with schizophrenia in Spanish isolate (2004) (0)
- Association of a D2 receptor gene polymorphism and schizophrenia in the spanish population (2003) (0)
- An association study of the 5-HT6 267-C/T variant and antipsychotic response (2001) (0)
- Partial agonism and schizophrenia Partial agonism and schizophrenia (2005) (0)
- O-24-4 rCBF in panic disorder and obsessive compulsive disorder (1996) (0)
- Olanzapine (2021) (0)
- Background Schizophrenia is amajor cause of suicide, and symptoms characteristic of treatment-resistant disease are strongrisk factors.Clozapine reduces symptomsin 60% of such patients and significantlydecreases the riskof (2003) (0)
- Serotonin, 5-HT2A receptor occupancy in vivo and response to the new atypical antipsychotic quetiapine (2000) (0)
- Dopamine D3 receptor and improvement in positive symptoms of schizophrenia (2002) (0)
- Analysis of serotonin transporter VNTR haplotypes in bipolar affective disorder (2006) (0)
- Setting Health Priorities (1999) (0)
- Increased hippocampal dendritic expression of non-phosphorylated MAP2 protein in schizophrenia (1998) (0)
- Association study of neuregulin 1 gene and schizophrenia in a population isolate from the north of Spain (2004) (0)
- Fluoxetine Supplement; ‘Journal’, September 1988, 153 (1989) (0)
- Atypical Antipsychotics Edited By B. A. Ellenbroek & A. R. Cools. Basel: Birkhäuser. 2000. 236 pp. ISBN 3 7643 59 48 X (2001) (0)
- Miscellaneous conditions and substances (2005) (0)
- Activation studies of medial temporal and frontal lobes in schizophrenia: A study using 99mTc-HMPAO spet (1993) (0)
- Functional D4 polymorphism in schizophrenics treated with clozapine (1993) (0)
- Atypical antipsychotics in the treatment of schizophrenia. Paper underrates patients' experience of extrapyramidal symptoms. (2001) (0)
- S-2-1 Imaging of neuroleptic occupancy in schizophrenia (1995) (0)
- The role of catenins and adenomatous polyposis colt (APC) in neurodevelopment: Abnormalities in focal cortical dysplasia (1998) (0)
- single photon emission tomography (SPET) agoraphobia, and post-traumatic stress disorder on 99mTcHMPAO Brain blood flow in anxiety disorders. OCD, panic disorder with (2011) (0)
- Human Dopamine D4 Gene Expression Using the Ribonuclease Protection Assay (1996) (0)
- The 5-HT 1C receptor gene and schizophrenia (1995) (0)
- CYP2D6 gene dosage and typical antipsychotic intolerance, drug induced parkinsonism, and tardive dyskinesia (2005) (0)
- Investigation of an association between a CYP1A2 5 ' flanking SNP (T-3591G) and response to clozapine (2001) (0)
- 5-HT2A and other serotonergic receptors: Genetic and clinical evidence for their involvement in schizophrenia (2000) (0)
- The dysbindin gene is associated with bipolar affective disorder (2005) (0)
- Acute effects of clomipramine on cortisol entry into the brain and the cerebrospinal fluid of guinea pigs (2002) (0)
- 5-HT receptors in schizoprhenia, genetic and clinical aspects (2000) (0)
- The 5HT2 Receptor As a Site for Antipsychotics (1996) (0)
- Human 5HT2C receptor: RNA editing and alternative splicing in schizophrenia vs control post-mortem brain (2004) (0)
- The pharmaco-economic aspects of dementia (2002) (0)
- Association between psychoses and allelic variation in 5-HT2A and 5-HT2C receptor genes (1996) (0)
- 511 A 1231 IBZM spet study of striatal D2 receptors in sertindole treated patients (1997) (0)
- The glutamate hypothesis of schizophrenia ∼ time to wake up the sleeping giant: A commentary on the paper (1996) (0)
- Immunoreactivity of Oct-6 in schizophrenia (2002) (0)
- The costs and benefits of clozapine therapy in the UK (1995) (0)
- Aripiprazole and sulpiride have differenzial effects on working memory performance and brain activity in patients with schizophrenia and healthy controls (2009) (0)
- Chronic in vitro treatments with desipramine, lithium, haloperidol and cortisol, influence glial cell numbers (2001) (0)
- Single nucleotide polymorphism in the alpha(1a)-adrenoceptor promoter is associated with response outcome to risperidone (2005) (0)
- The Pharmaco-economics of Schizophrenia: New Horizons (1996) (0)
- Genetic variation in the 5-HT3 receptor gene: No association with schizophrenia or drug response (1998) (0)
- Left lateralised asymmetry of striatal D2 receptor binding in antipsychotic free schizophrenic patients - A 123I IBZM spet study (1993) (0)
- 5-HT 2 A RECEPTOR BLOCKADE BY QUETIAPINE IS RELATED TO ITS SIDE EFFECT PROFILE (2000) (0)
- The Genetics of Antipsychotic Response: Pharmacogenetic and Pharmacogenomic Investigations and Clinical Applications (2016) (0)
- S.07.05 Advances in the pharmacogenetic prediction of clozapine response (2003) (0)
- The Department of Neuroscience at the Institute of Psychiatry (1992) (0)
- An investigation of a structural polymorphism in the mGluR7 gene in association with schizophrenia (1999) (0)
- An association study of a D3 polymorphism with atypical antipsychotic response (2001) (0)
- S.4.07 Applications of pharmacogenetics and pharmacogenomics in the improvement of psychiatric treatment (2004) (0)
- 104. D2 dopamine receptor blockade with the atypical antipsychotics remoxipride and risperidone: a 123I-IBZM SPET study (1994) (0)
- RNA editing of the 5-HT2C receptor in human brain (2000) (0)
- The serotonin 5HT2C-244(CT) repeat polymorphism does not influence susceptibility to schizophrenia or outcome to olanzapine treatment (2003) (0)
- ADRA1A promoter SNP associated with negative symptom improvement in olanzapine response (2004) (0)
- Positive association between a novel dinucleotide repeat polymorphism in the human serotonin-3B receptor gene (5HT3B) and clinical response to clozapine (2000) (0)
- Regional cerebral blood flow in obsessive‐compulsive disorder measured by 99Tcm‐HMPAO uptake and SPET: Differential correlates with obsessive‐compulsive and anxious‐avoidant features (1995) (0)
- Olanzapine (1997) (0)
- Schizophrenia: A Neurodevelopment al Perspective (1993) (0)
- An investigation in cells, animals and humans (2002) (0)
- In defence of clozapine (1993) (0)
- WHY IS A PARTIAL AGONIST OF THEORETICAL INTEREST INSCHIZOPHRENIA? (2004) (0)
- Investigation of muscarinic 1 promoter polymorphisms on receptor expression and outcome to antipsychotic treatment (2002) (0)
- Cholinesterase inhibitors in Alzheimer's disease: sooner or later or both? (2006) (0)
- Expression of developmentally specific isoforms on non-NMDA mRNAs in the hippocampus of schizophrenics (1995) (0)
- ANALYSIS OF RECEPTOR SYSTEMS IN SCHIZOPHRENIA USING TISSUE OBTAINED AT AUTOPSY AND NEUROIMAGING (2019) (0)
- Choline-acetyltransferase gene variants and their influence in schizophrenia and antipsychotic response (2007) (0)
- Ziprasidone : a viewpoint by robert kerwin. (1997) (0)
- Delineating the influence of ANKK1 and dopamine 2 receptors in schizophrenia (2005) (0)
- 5-HT2A polymorphisms and mental disorders (1996) (0)
- Association between psychoses and allelic variation in the 5-HT2C receptor gene (1996) (0)
- Association between the serotonin transporter linked polymorphic region gene (5-HTTLPR) and response to TCAs (2003) (0)
- 176 – Stargazin involvement with bipolar disorder and response to lithium treatment (2008) (0)
- Recent advances of pharmacogenetics in psychiatry (2000) (0)
- Association study between genetic variants in the alpha- adrenergic receptor genes and bipolar affective disorder (1999) (0)
- GABAA receptor density and clinical dimensions of schizophrenia: A 123I‐Iomazenil SPET investigation (1995) (0)
- Plasma level monitoring of psychotropics and anticonvulsants (2005) (0)
- Research accreditation of seniors (1992) (0)
- P.3.c.068 Olanzapine orodispersible vs haloperidol both associated with lorazepam in the treatment of agitation (2008) (0)
- An autoradiographic study of cholecystokinin receptors in the temporal lobe in post-mortem schizophrenic brains (1991) (0)
- Further evidence for association between polymorphisms in the 5-HT2A receptor gene and clozapine response (1998) (0)
- 231 Quantitative analysis of dopamine D4 gene expression in control and schizophrenic post mortem tissue (1997) (0)
- In Vivo Studies of Dopamine D2 Receptor Binding in Schizophrenia by 1231 Iodobenzamide (IBZM) and Single Photon Emission Tomography (SPET) (1994) (0)
- Analysis of muscarinic 1 promoter polymorphisms on receptor expression and outcome to atypical antipsychotic treatment (2003) (0)
- 46. Regional cerebral blood flow (rCBF) in schizophrenia during verbal memory activation: a 99Tcm-HMPAO split-dose single photon emission tomographic study (1993) (0)
- Antidepressants and schizophrenia (1999) (0)
- Allelic association between a ser-9-gly polymorphism in the D3 receptor gene and schizophrenia (1996) (0)
- Analyses of clozapine response and the 5-HT2 gene (1995) (0)
- Ziprasidoneof its Use in Schizophrenia and Schizoaffective Disorder (2002) (0)
- Modulation of the multiple drug resistance glycoprotein by protein kinase-A is relevant for glucocorticoid receptor function (2000) (0)
- Effects of the-1438-A/G serotonin 2A receptor promotor polymorphism on expression (2001) (0)
- Clozapine (1992) (0)
- Reduced GABA benzodiazepine receptor in the absence of atrophy in alcohol dependency: an 123I-Iomazenil SPET and MRI study (1997) (0)
- Pharmacogenomics of antipsychotic drugs (2003) (0)
- Functional neuroimaging in Alzheimer's disease: how far should we go? (1994) (0)
- Development of a new green fluorescent protein-glucocorticoid receptor (GR) chimera to evaluate the effects of antidepressants and other steroid-independent activators of the GR (2000) (0)
- Sainsbury's Key to Psychiatry. (4th edn) By M. J. Sainsbury and L. G. Lambeth Chichester: John Wiley and Sons. 1988. 519 pp. £15.95. (1991) (0)
- S-9-3 Pharmacological genetic association studies and clozapine response (1996) (0)
- Glutamate receptors and effector mechanisms in postmortem temporal lobe in schizophrenia (1989) (0)
- Neuroendocrine evidence for serotonergic involvement in clinical response to clozapine (1995) (0)
- Striatal D2 blockade and depression in schizophrenia — preliminary spet findings (2000) (0)
- Reply to commentaries (1997) (0)
- OLANZAPINE. AUTHOR'S REPLY (1997) (0)
- Clozapine pharmacokinetics studied with CYP1A2 knockout mice (2000) (0)
- PSM volume 21 issue 4 Cover and Front matter (1991) (0)
- No association between alpha1A-adrenergic receptor gene polymorphism and schizophrenia or antipsychotic treatment (2003) (0)
- Association between a 2030-G/A substitution in the human myo-inositol monophosphatase gene (IMPA) and bipolar disorder and schizophrenia (1999) (0)
- In Vivo Receptor Spet Studies of Antipsychotic Drug Action (1996) (0)
- Novel polymorphisms in the histamine 1 and 2 receptor genes, schizophrenia and clozapine drug response (2000) (0)
- Delusions-New Trends in Diagnosis and Treament ( Organised by the AEP Section on Psychopathology ) (2004) (0)
- Pharmacogenetics and Pharmacogenomics in Psychiatry: Clinical Applications (2007) (0)
- P.2.051 Modulation of glucocorticoid function in human whole-blood by antidepressants (2005) (0)
- 244 An investigation of the GLUR6 receptor gene (GRIK2) in schizophrenia (1997) (0)
- The test/retest stability of in vivo Single Photon Emission Tomography (SPET) estimates of cortical 5-HT2A receptors (2000) (0)
- Genetic indicators of response to olanzapine treatment (2002) (0)
- Clozapine and Prevention of Suicide in Schizophrenia (2003) (0)
- Depression and anxiety (2005) (0)
- The NMDAR1 receptor gene and schizophrenia (1998) (0)
- Association analysis of polymorphism (ARG492CYS) in the α1A-adrenergic receptor gene with schizophrenia and antipsychotic treatment (2003) (0)
- GABAA receptor changes in schizophrenia is assessed using 123I-iomazenil single photon emission tomography (SPET). A preliminary report (1995) (0)
- Identifying factors predisposing to inpatient violence (2004) (0)
- Polymorphisms in the dopamine D3 receptor gene and improvement in positive symptoms of schizophrenia (2003) (0)
- It's a SNP – a loose-leaf bible for bioentrepreneurs (2001) (0)
- S-30-2 Glutamatergic abnormalities in the temporal lobe in schizophrenia (1996) (0)
- Hiv is Associated with Ampa Neurotoxicity in the Cerebellum (1995) (0)
- 237 No association between a novel polymorphism in the 5-HT4 receptor gene and response to clozapine (1997) (0)
- Current Biological Research in Schizophrenia (1989) (0)
- Investigating the influence of ChAt gene polymorphisms in schizophrenia and olanzapine drug therapy among Basque and Spanish patients (2004) (0)
- Social behaviour in a cohort of 91 clozapine treated patients in the UK (2000) (0)
- The impact of clozapine treatment duration on NHS costs (2000) (0)
- Association analysis of two polymorphisms in the promoter region of the alpha-2A-adrenergic receptor gene with psychosis and olanzapine treatment (2002) (0)
- The-1438-A/G serotonin 2A receptor promoter polymorphism affects promoter expression (2002) (0)
- P.1.07 Gene expression profiling to identify new targets associated with schizophrenia and its treatment (2004) (0)
- Investigation of a novel muscarimc 1 receptor polymorphism in receptor expression and outcome to olanzapine treatment (2002) (0)
- Children and adolescents (2009) (0)
- 234 Pharmacogenetic factors in treatment-resistant schizophrenia: The role of CYP2D6 variants (1997) (0)
- 513 Striatal D2 receptor binding in olanzapine treated patients estimated by 123I IBZM spet (single photon emission tomography) (1997) (0)
- A naturalistic study of response to clozapine following failure to respond to olanzapine (2003) (0)
- Glycogen synthase kinase 3β in the hippocampus in schizophrenia (2000) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Robert W. Kerwin?
Robert W. Kerwin is affiliated with the following schools:
